Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study - Pivonello, R; Petersenn, S; Newell-Price, J; Findling, J W; Gu, F; Maldonado, M; Trovato, A; Hughes, G; Salgado, L R; Lacroix, A; Schopohl, J; Biller, B MPasireotide B2305 Study Group (Clin Endocrinol (Oxf), 2014)